The tablet formulation of levothyroxine requires gastric pH in order to dissolve and be appropriately absorbed by the intestine. Interference from other treatments such as proton-pump inhibitors, however, may prevent proper absorption.
Recently, new levothyroxine formulations have been developed, some of which are now available in some countries. One such new formulation is a liquid oral solution that does not require dissolution for absorption.
To determine whether the liquid oral solution prevents the malabsorption caused by proton-pump inhibitors, researchers evaluated outcomes in patients before or after switching from the tablet to liquid formulation.
Their results provide insight into the potential of novel levothyroxine formulations in improving patient outcomes.
READ FULL ARTICLE From press.endocrine.org